Brett Sealove, MD
Nuclear Cardiology · Eatontown, NJNPI 1528239050
Payments from drug & device makers
Across 550 payments — averaging $760.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Orapharma, A Division Of Bausch Health US, LLC$192K
- Johnson & Johnson$152K
- Amgen$25K
- E.r. Squibb & Sons, L.L.C.$12K
- Novartis$9K
- Boston Scientific$7K
- plus $22K from 19 others
What the payments were for
- Consulting fees$69,79217%
- Speaking & faculty fees$278,95268%
- Travel & lodging$47,35012%
- Food & beverage$13,4063%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Orapharma, A Division Of Bausch Health US, LLC | 253 | $192,060 |
| Johnson & Johnson | 120 | $151,865 |
| Amgen | 31 | $25,120 |
| E.r. Squibb & Sons, L.L.C. | 37 | $11,560 |
| Novartis | 4 | $9,054 |
| Boston Scientific | 10 | $6,510 |
| Bausch Health US, LLC | 2 | $4,700 |
| Amarin Pharma, Inc. | 3 | $3,893 |
| Abbott | 32 | $3,633 |
| Idorsia Pharmaceuticals US Inc | 1 | $3,540 |
| Medtronic(2 entities) | 25 | $2,637 |
| Janssen Scientific Affairs, LLC | 1 | $2,500 |
| Heartflow, Inc. | 5 | $323 |
| Integra Lifesciences Corporation | 2 | $321 |
| Abiomed | 1 | $146 |
| Smith+Nephew | 1 | $132 |
| Davol Inc. | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $107 |
| Portola Pharmaceuticals, LLC | 6 | $86 |
| AstraZeneca(2 entities) | 4 | $55 |
| Pfizer | 3 | $48 |
| Cvrx, Inc. | 3 | $35 |
| Cleerly, Inc. | 1 | $28 |
| Siemens Medical Solutions USA, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARESTIN$157,336
- XARELTO$152,865
- Repatha$24,932
- Watchman$6,000
- CAMZYOS$5,202
- APLENZIN$4,700
- Vascepa$3,893
- QUVIVIQ$3,540
- MitraClip$1,357
- Mitra Clip system$1,204
- INTEGRA$964
- SYMPLICITY G3$743
- INTEGRA DERMAL REGENERATION TEMPLATE$321
- PRIMATRIX$321
- ONYX FRONTIER$287
- GENERAL - THERAPIES$263
- FFRct$242
- Xience Sierra Coronary Stent System$140
- PICO Single Use Negative Pressure Wound Therapy$132
- MitraClip System$127
How this compares
$418,511 in reported general payments places this provider in the 95th percentile of 34 nuclear cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 593 | $661,670 |
| EliquisApixaban | 408 | $477,477 |
| Repatha SureclickEvolocumab | 239 | $182,268 |
| EntrestoSacubitril/Valsartan | 38 | $54,919 |
| NexlizetBempedoic Acid/Ezetimibe | 46 | $48,352 |
| Praluent PenAlirocumab | 50 | $46,929 |
| MultaqDronedarone Hcl | 30 | $44,643 |
| VascepaIcosapent Ethyl | 54 | $30,742 |
| Icosapent Ethyl | 64 | $24,168 |
| Rosuvastatin Calcium | 1,440 | $20,531 |
| Ezetimibe | 596 | $17,497 |
| FarxigaDapagliflozin Propanediol | 16 | $15,437 |
| Metoprolol Succinate | 888 | $13,834 |
| Cardizem CdDiltiazem Hcl | 13 | $13,613 |
| LipitorAtorvastatin Calcium | 16 | $12,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $151,865 | $661,670593 claims |
| PfizerEliquis, Lipitor | $48 | $489,862424 claims |
| NovartisEntresto | $9,054 | $54,91938 claims |
| AstraZenecaFarxiga, Crestor | $55 | $24,10228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 34 nuclear cardiology providers in New Jersey.
Other nuclear cardiology in Eatontown
- Alexey TatusovEatontown$2K
- Richard TangelEatontown$2K
- Steven DanielsEatontown$905
- Jeffrey OsofskyEatontown$752
- Marcia LiuEatontown$622
- Madhav UpadhyayaTinton Falls$89K
- Mark FinchCherry Hill$79K
- Scott GablerVoorhees$74K
- Nasser ChaudhryCherry Hill$49K
- Thomas GalskiMoorestown$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.